Evidence map›Paper›PMID 41398167›Full record

ArticleNPJ vaccines2025

Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits.

Frederik Radvan, Alexandra Hauser, Li-Yun Lin, Sarah Wilmschen-Tober, Marion Schaber, Marta Bermejo-Jambrina, Tariq Oluwakunmi Agbabiaka, David Peterhoff, Lydia Riepler, Nadja Mendrzyk and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Frederik RadvanDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Alexandra HauserInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Li-Yun LinInserm U1109, Institute of Hematology and Immunology, University of Strasbourg, Strasbourg, France.
Sarah Wilmschen-ToberDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Marion SchaberDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Marta Bermejo-JambrinaDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Tariq Oluwakunmi AgbabiakaDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
David PeterhoffInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Lydia RieplerDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Nadja MendrzykDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Anja BeierfußCentral Laboratory Animal Facility, Medical University of Innsbruck, Innsbruck, Austria.
Cornelia SpethDepartment of Hygiene, Microbiology and Virology, Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Christiane MoogInserm U1109, Institute of Hematology and Immunology, University of Strasbourg, Strasbourg, France.ORCID http://orcid.org/0000-0002-0916-156X
Dorothee von LaerDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Ralf WagnerInstitute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Janine KimpelDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria. Janine.Kimpel@i-med.ac.at.ORCID http://orcid.org/0000-0002-5210-7905

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) Project HIVacToGC, Grant 16GW0363KEC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 681032 (EHVA, European HIV Vaccine Alliance)
6 · The paper itself

Abstract

Developing an effective human immunodeficiency virus (HIV) vaccine remains challenging due to difficulties to induce antibodies that neutralize the wide range of HIV-variants. Native-like HIV envelope (Env) trimers in a closed conformation represent promising immunogens. We evaluated the immunogenicity of the chimeric vesicular stomatitis virus-based vector VSV-GP encoding clade C membrane-tethered native-like trimers in heterologous prime/boost combinations with autologous protein. Infected cells displayed high levels of native-like trimers on the surface in a favorable conformation and native-like trimers were also efficiently incorporated into VSV-GP particles. Heterologous vector/protein immunizations outperformed homologous vector regimens, regardless of administration order. In rabbits, these regimens elicited Tier 1 and autologous Tier 2 neutralizing antibodies. Tier 2 neutralization was restricted to pseudoviruses matching the engineered Env-immunogen, with no cross-neutralization of parental Env-variants. Our findings support the use of VSV-GP as a potent platform for displaying native-like Env-trimers and highlight its potential in prime-boost strategies for HIV vaccine development.

Identifiers

PMID41398167
PMCPMC12816742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.